Our offerings
Market Access Strategy, HTA, and Health Economics
Nordic RWE & Evidence Generation
AI & Dashboard Solutions
Policy Shaping & Life Science Consulting
Our work
The latest
Our people
Careers
Contact us
NICE recommends cemiplimab for recurrent or metastatic cervical cancer
NICE recommends first new NHS treatment in over 20 years for women with resistant ovarian cancer
NICE opens routine NHS access to SMA treatments
NICE approves givinostat for Duchenne muscular dystrophy
NICE greenlights Rystiggo for uncontrolled gMG via interim NHS funding
NICE recommends zanidatamab for HER2-positive advanced biliary tract cancer
NICE backs Jaypirca in draft guidance for relapsed CLL
NICE recommends Blenrep for relapsed multiple myeloma
NICE seeks feedback on new EQ-5D-5L value set
NICE sets a dedicated fertility pathway for endometriosis
1
2
Next
Menu
